TransMedics Group - TMDX Stock Forecast, Price & News

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $46.00 to $58.00 in a report on Thursday, August 4th. Cowen increased their price objective on shares of TransMedics Group from $39.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, July 26th. Oppenheimer increased their price objective on shares of TransMedics Group from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, August 2nd. JPMorgan Chase & Co. upgraded shares of TransMedics Group from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $26.00 to $48.00 in a report on Tuesday, August 2nd. Finally, Cowen raised their target price on shares of TransMedics Group from $45.00 to $50.00 in a report on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, TransMedics Group has an average rating of "Moderate Buy" and an average price target of $46.00.

TransMedics Group Price Performance

NASDAQ:TMDX traded up $0.60 during trading hours on Monday, reaching $47.60. 271,474 shares of the company's stock were exchanged, compared to its average volume of 287,839. The business's 50-day simple moving average is $34.49 and its two-hundred day simple moving average is $26.60. TransMedics Group has a 12 month low of $10.00 and a 12 month high of $49.27. The company has a quick ratio of 3.41, a current ratio of 4.18 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.34 billion, a P/E ratio of -27.67 and a beta of 1.63.

TransMedics Group (NASDAQ:TMDX - Get Rating) last posted its quarterly earnings data on Monday, August 1st. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative return on equity of 74.20% and a negative net margin of 92.76%. During the same quarter last year, the business posted ($0.39) earnings per share. Sell-side analysts expect that TransMedics Group will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP John F. Carey sold 3,320 shares of the firm's stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $32.59, for a total value of $108,198.80. Following the completion of the transaction, the vice president now owns 379 shares of the company's stock, valued at approximately $12,351.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other TransMedics Group news, VP John F. Carey sold 3,000 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $41.27, for a total value of $123,810.00. Following the completion of the sale, the vice president now owns 771 shares in the company, valued at approximately $31,819.17. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP John F. Carey sold 3,320 shares of the stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $32.59, for a total transaction of $108,198.80. Following the completion of the sale, the vice president now owns 379 shares of the company's stock, valued at approximately $12,351.61. The disclosure for this sale can be found here. In the last 90 days, insiders sold 151,814 shares of company stock valued at $5,633,336. Company insiders own 8.70% of the company's stock.